Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Luke Fischer

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Practical Neurology (Fort Washington, Pa.)|August 4, 2023
A Precision Medicine Approach to Dementia Care: Syndrome, Etiology, and CopathologyD Luke Fischer, William W Seeley
Movement Disorders : Official Journal of the Movement Disorder Society|November 16, 2018
BDNF provides many routes toward STN DBS-mediated disease modificationD Luke Fischer, Caryl E Sortwell
Annals of Neurology|October 7, 2017
Can STN DBS protect both nigral somata and innervation of the striatum?D Luke Fischer, Fredric P Manfredsson, Caryl E Sortwell
Alzheimer'S & Dementia (Amsterdam, Netherlands)|July 2, 2026
FTLD-TDP versus LATE-NC: Experience of a Brain Bank specializing in FTLD-TDPD Luke Fischer, Salvatore Spina, Bruce L Miller, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Basic Science and PathogenesisD Luke Fischer, Salvatore Spina, Bruce L Miller, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 20, 2017
Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease ModelsXiaomin Su, D Luke Fischer, Xin Li, et al.
Neurosurgery|April 5, 2018
External Ventricular Drain Placement Accuracy and Safety When Done by Midlevel PractitionersNathaniel R Ellens, D Luke Fischer, Jason E Meldau, et al.
Frontiers in Neuroscience|September 21, 2018
Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's DiseaseMegan F Duffy, Timothy J Collier, Joseph R Patterson, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 28, 2015
Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's DiseaseD Luke Fischer, Sara E Gombash, Christopher J Kemp, et al.
Parkinsonism & Related Disorders|May 16, 2018
Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's diseaseD Luke Fischer, Peggy Auinger, John L Goudreau, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Practical Neurology (Fort Washington, Pa.)|August 4, 2023
A Precision Medicine Approach to Dementia Care: Syndrome, Etiology, and CopathologyD Luke Fischer, William W Seeley
Movement Disorders : Official Journal of the Movement Disorder Society|November 16, 2018
BDNF provides many routes toward STN DBS-mediated disease modificationD Luke Fischer, Caryl E Sortwell
Annals of Neurology|October 7, 2017
Can STN DBS protect both nigral somata and innervation of the striatum?D Luke Fischer, Fredric P Manfredsson, Caryl E Sortwell
Alzheimer'S & Dementia (Amsterdam, Netherlands)|July 2, 2026
FTLD-TDP versus LATE-NC: Experience of a Brain Bank specializing in FTLD-TDPD Luke Fischer, Salvatore Spina, Bruce L Miller, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Basic Science and PathogenesisD Luke Fischer, Salvatore Spina, Bruce L Miller, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 20, 2017
Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease ModelsXiaomin Su, D Luke Fischer, Xin Li, et al.
Neurosurgery|April 5, 2018
External Ventricular Drain Placement Accuracy and Safety When Done by Midlevel PractitionersNathaniel R Ellens, D Luke Fischer, Jason E Meldau, et al.
Frontiers in Neuroscience|September 21, 2018
Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's DiseaseMegan F Duffy, Timothy J Collier, Joseph R Patterson, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 28, 2015
Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's DiseaseD Luke Fischer, Sara E Gombash, Christopher J Kemp, et al.
Parkinsonism & Related Disorders|May 16, 2018
Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's diseaseD Luke Fischer, Peggy Auinger, John L Goudreau, et al.
Pageof 3